Get started
GEHEALTHCAREDRNGEHEALTHCAREDRNGEHEALTHCAREDRN

GEHEALTHCAREDRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Seasonals Bonds

GEHC34 trade ideas

GEHC: Approaching support with potential rebound toward 100GEHC recently began to pull back from 94.55 towards a support zone below 77, with the first major support around 75. If the stock holds above this level, it is highly likely to see a gradual rise toward the 100 and 120 target zones, potentially reaching these levels by June 2025. The stock has significant growth potential in the future if it manages to establish itself above the 100 mark. GE HealthCare Technologies (GEHC) separated from General Electric (GE) and started operating as an independent company in early 2023. It specializes in developing healthcare technologies, with a focus on medical imaging, patient monitoring, and diagnostic tools.
NASDAQ:GEHCLong
by Quantific-Solutions
GEHC 1H Long Swing Aggressive Trend TradeAggressive Trend Trade - short impulse + volumed T1 + support level + volumed 2Sp- + weak test + first bullish bar closed entry Calculated affordable stop limit 1 to 2 R/R take profit Daily Trend "+ long impulse + T2 level + 1/2 correction + support level + volumed 2Sp- - independent approach" Monthly trend "+ long impulse + SOS test level + 1/2 correction + support level + volumed 2Sp+ + weak test" GEHC @NASDAQ.NMS Sell Stop 79.68 LMT 81.40, GTC Sell Limit 84.76, GTC
NASDAQ:GEHCLong
by MishaSuvorov
GEHC 1H Swing Long Aggressive Trend TradeAggressive Trend Trade - short impulse - unvolumed T1 level + biggest volume 2Sp+ + weak test + first bullish bar closed entry Calculated affordable stop limit Take profit: - 60% 1 to 2 R/R - 40% daily T1 Daily context "- short impulse - unvolumed T1 level + biggest volume 2Sp+ + weak test + first bullish bar closed entry" Monthly context "+ long impulse + T2 level + 1/2 correction + support level + volumed manipulation" GEHC @NASDAQ.NMS Sell Limit 83.59, GTC Sell Stop 79.59 LMT 80.69, GTC GEHC @NASDAQ.NMS Sell Limit 82.85, GTC GEHC @NASDAQ.NMS Sell Stop 79.59 LMT 80.69, GTC
NASDAQ:GEHCLong
by MishaSuvorov
GE HealthCare | GEHCGE Healthcare aka GEHC is a renowned global medical technology, pharmaceutical diagnostics, and digital solutions company that aims to revolutionize healthcare by eliminating limits. With a diverse portfolio of innovative products, services, and solutions, GEHC empowers healthcare professionals to make informed decisions quickly and improve patient care across the entire healthcare continuum. This article delves into the key aspects of GE Healthcare, including its business segments, macro trends driving growth, management incentives, financial performance, competitors, and valuation. GE Healthcare operates in four business segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. These segments cater to healthcare providers and researchers worldwide, offering a wide range of products and solutions that enhance clinical decision-making and patient outcomes. The company's revenue streams come from the sale of medical devices, consumable products, services, and digital solutions. By focusing on customer-driven innovation, industry-leading service capabilities, and integrated digital solutions, GEHC continually improves the performance, quality, and customer experience of its offerings. GE Healthcare benefits from several macro trends that are shaping the healthcare industry. The growing adoption of precision health, fueled by advancements in genomics, personalized medicine, and targeted therapies, presents opportunities for GEHC to develop tailored solutions. The global precision medicine market is projected to reach $278.3 billion by 2027, with a CAGR of 10.5%. Additionally, the market for genomic testing is expected to reach $30.9 billion by 2027, growing at a CAGR of 14.7%. The digitization of healthcare through AI and machine learning enables the analysis of vast amounts of patient data for more accurate diagnoses and treatment decisions. The global healthcare artificial intelligence market is predicted to reach $31.3 billion by 2025, growing at a CAGR of 41.5%. Furthermore, increasing demand for healthcare services driven by demographic trends and improving access to healthcare in emerging markets further support GEHC's growth trajectory. With personalized medicine estimated to have a market value of $3,168.0 billion by 2027, GEHC is well positioned to leverage these trends and provide innovative solutions to meet the evolving needs of the healthcare industry (Sources: Grand View Research, Fortune Business Insights, Allied Market Research, MarketsandMarkets). GEHC CEO, Peter J. Arduini, has improved incentives in place to drive the company's performance. With an amended offer letter, Arduini's base salary increased to $1,250,000, accompanied by an annual target bonus of 150% of his base salary and an annual long-term incentive grant target of $11,875,000 starting in 2023. These incentives provide a strong motivation for Arduini to lead GEHC's growth and success, enhancing shareholder value. In 2022, GEHC reported total revenue of $18.34 billion, representing a favorable increase compared to the previous year. Although the profitability declined in the final quarter, the company's operating cash flow and adjusted EBIT margin showed positive trends. GEHC guided organic revenue growth of 5% to 7% for 2023, along with higher adjusted EBIT margin and EPS ranges. The company's commitment to achieving a free cash flow conversion target of 85% or more further reinforces its positive financial outlook. GEHC faces competition from prominent players in the medical technology industry, including Philips Healthcare, Draeger, Mindray, Masimo, and Baxter. In specific segments, GEHC competes with Siemens Healthineers, Canon, Fujifilm, Carestream, Hologic, and other companies. Despite competition, GEHC's comprehensive product portfolio, customer-focused approach, and commitment to innovation position it well in the market. GE Healthcare stands out from its competitors in the healthcare sector due to its robust portfolio of cutting-edge products and data-driven solutions. The company's commitment to innovation and advanced technologies enables it to offer unique offerings that address the evolving needs of the industry. One key area where GEHC excels is precision health. Leveraging advancements in genomics, personalized medicine, and targeted therapies, GEHC develops tailored solutions that provide precise and effective treatments for patients. For example, its innovative imaging technologies, such as magnetic resonance imaging (MRI) and computed tomography (CT), enable high-resolution visualization of anatomical structures, aiding in the accurate diagnosis and monitoring of various medical conditions. Moreover, GEHC is at the forefront of the digital revolution in healthcare. By harnessing the power of artificial intelligence (AI) and machine learning, GEHC's products analyze vast amounts of patient data to deliver more accurate diagnoses and treatment decisions. For instance, its AI-powered imaging software can detect and analyze anomalies in medical images, helping clinicians detect diseases at an early stage and enhance treatment outcomes. This data-driven approach not only improves patient care but also increases operational efficiency in healthcare facilities. GEHC's commitment to delivering innovative solutions is further reflected in its diverse product offerings. The company provides a wide range of medical devices, including ultrasound systems, patient monitors, anesthesia machines, and diagnostic imaging equipment. These products are designed to meet the unique needs of healthcare providers and patients, empowering clinicians to make informed decisions and improving patient outcomes. Based on a valuation analysis using trading multiples of similar companies, GEHC's value is estimated to range from $55 billion to $81 billion. Taking the midpoint of this range, the company's estimated enterprise value (EV) is $64 billion, suggesting a potential stock price of $125. This valuation indicates a significant upside potential of at least 66% within 18 to 24 months from the current price. With its strong market position, growth opportunities, and commitment to advancing healthcare, GEHC presents an attractive investment prospect. GE Healthcare is a leading global medical technology and digital solutions company with a clear mission to transform healthcare. With its diverse portfolio of products, services, and solutions, GEHC is well-positioned to capitalize on the growing demand for precision health, digitization, and improved access to healthcare. The company's financial performance, management incentives, and competitive landscape further support its growth potential. Considering the estimated valuation, GE Healthcare's stock price has the potential to increase significantly in the next 1.5 to 2 years, offering investors an opportunity for substantial returns.
NASDAQ:GEHCLong
by moonypto
GEHC topped out in an ascending channel SHORTGEHC is a new spinoff from General Electric. It has great success thus far with good earnings reports and no dependency on debt and interest rates. It has been on an uptrend since the November earnings. At present it is correcting. I will play this going short on shares while hedging with a long term call options. I am in GE calls out into 2026. A long term call option will yield a lower capital gains tax if closed beyond 12 months. Accordingly, I will go out 15-16 months as I typically want to close early to avoid the effects of time decay. I have high expectations for GEHC. I do not think it will disappoint. When price reaches the running mean anchored VWAP I will close the shares and run only the options.
NASDAQ:GEHCLong
by AwesomeAvani
GE HealthCare Surpasses Expectations with Strong Q4 PerformanceGeneral Electric's healthcare division (NASDAQ: NASDAQ:GEHC ), GE HealthCare, has emerged as a standout performer in the fourth quarter, exceeding both revenue and earnings estimates. Despite ongoing challenges in the global market, the company has demonstrated resilience and delivered robust financial results, much to the delight of investors and analysts alike. Earnings Overview GE HealthCare's (NASDAQ: NASDAQ:GEHC ) adjusted annual profit forecast of $4.20 to $4.35 per share signals a promising outlook for the company. This projection, surpassing analysts' estimates, reflects the effectiveness of the company's strategic initiatives and operational efficiency measures. With the midpoint of the forecast exceeding expectations, GE HealthCare (NASDAQ: NASDAQ:GEHC ) is poised for sustained growth and profitability in the coming quarters. The impressive earnings performance in the fourth quarter further underscores GE HealthCare's (NASDAQ: NASDAQ:GEHC ) resilience and ability to navigate through challenging economic conditions. Excluding items, the company reported earnings of $1.18 per share, comfortably surpassing analysts' estimates of $1.07. This notable achievement reflects the strength of GE HealthCare's diversified portfolio and its ability to capitalize on emerging opportunities in the healthcare sector. Revenue Result Moreover, GE HealthCare's (NASDAQ: NASDAQ:GEHC ) robust revenue of $5.21 billion in the fourth quarter highlights its strong market position and competitive advantage. The company's ability to beat analysts' revenue expectations by a significant margin demonstrates its continued focus on driving top-line growth through innovation and customer-centric solutions. With a solid pipeline of products and services, GE HealthCare (NASDAQ: NASDAQ:GEHC ) is well-positioned to capitalize on evolving market trends and emerging opportunities in the healthcare industry. Investors Sentiment Investors have reacted positively to GE HealthCare's (NASDAQ: NASDAQ:GEHC ) stellar performance, with the company's stock price witnessing a notable uptick following the earnings announcement. This vote of confidence from the market underscores the strong fundamentals and growth prospects of GE HealthCare, reaffirming its status as a key player in the healthcare ecosystem. Conclusion: In conclusion, GE HealthCare's (NASDAQ: NASDAQ:GEHC ) impressive fourth-quarter performance underscores its resilience, strategic agility, and commitment to driving value for its stakeholders. With a robust earnings forecast, strong revenue growth, and a track record of innovation, the company is well-positioned to capitalize on emerging opportunities and deliver sustainable long-term growth. As GE HealthCare (NASDAQ: NASDAQ:GEHC ) continues to expand its footprint and strengthen its market presence, investors can look forward to continued value creation and success in the dynamic healthcare landscape.
NASDAQ:GEHCLong
by DEXWireNews
$GEHC Long term for portfolioNASDAQ:GEHC GE Healthcare has been spun off for over a year now and for as old of a company it is I think there will be room for growth. We are just starting to see the new identity this company will be taking on with the recent acquisition in the AI field. Compared to its peers its trading at a much lower PE ratio. Possibly setting this up to be a value play when rates come down in the 2nd half of this year. While I don't mind seeing growth by acquisition keeping long term debt down is key and they have taken on a healthy chunk. As long as GEHC can see real revenue production and synergies from these acquisitions while also producing great products through it's own R & D I have full confidence that positive free cash flow will continue to grow and the dividend will expand at a good pace making this a long term compounding stock through the next decade. I am long GEHC with half positioning and will be adding on dips to the longer term trend line. *this is not financial advice. Invest at your own risk*
NASDAQ:GEHCLong
by mwilber34
GE HEALTHCARE Stock Chart Fibonacci Analysis 071623 Trading Idea 1) Find a FIBO slingshot 2) Check FIBO 61.80% level 3) Entry Point > 81/61.80% Chart time frame : B A) 15 min(1W-3M) B) 1 hr(3M-6M) C) 4 hr(6M-1year) D) 1 day(1-3years) Stock progress : A A) Keep rising over 61.80% resistance B) 61.80% resistance C) Hit the bottom D) Hit the top Stocks rise as they rise from support and fall from resistance. Our goal is to find a low support point and enter. It can be referred to as buying at the pullback point. The pullback point can be found with a Fibonacci extension of 61.80%. This is a step to find entry level. 1) Find a triangle (Fibonacci Speed Fan Line) that connects the high (resistance) and low (support) points of the stock in progress, where it is continuously expressed as a Slingshot, 2) and create a Fibonacci extension level for the first rising wave from the start point of slingshot pattern. When the current price goes over 61.80% level , that can be a good entry point, especially if the SMA 100 and 200 curves are gathered together at 61.80%, it is a very good entry point. As a great help, tradingview provide these Fibonacci speed fan lines and extension levels with ease. So if you use the Fibonacci fan line, the extension level, and the SMA 100/200 curve well, you can find an entry point for the stock market. At least you have to enter at this low point to avoid trading failure, and if you are skilled at entering this low point, with fibonacci6180 technique, your reading skill to chart will be greatly improved. If you want to do day trading, please set the time frame to 5 minutes or 15 minutes, and you will see many of the low point of rising stocks. If want to prefer long term range trading, you can set the time frame to 1 hr or 1 day.
NASDAQ:GEHC
by fibonacci6180
1